<html xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:dt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./3975b1-06-preclinical-2_files/filelist.xml">
<title>Preclinical Review/additional information</title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>CDRH</o:Author>
  <o:LastAuthor>Jenny Butler</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>2</o:TotalTime>
  <o:LastPrinted>2003-07-30T21:01:00Z</o:LastPrinted>
  <o:Created>2003-07-30T21:02:00Z</o:Created>
  <o:LastSaved>2003-07-30T21:02:00Z</o:LastSaved>
  <o:Pages>9</o:Pages>
  <o:Words>3754</o:Words>
  <o:Characters>21400</o:Characters>
  <o:Company>FDA/CDRH</o:Company>
  <o:Lines>178</o:Lines>
  <o:Paragraphs>42</o:Paragraphs>
  <o:CharactersWithSpaces>26280</o:CharactersWithSpaces>
  <o:Version>9.3821</o:Version>
 </o:DocumentProperties>
 <o:CustomDocumentProperties>
  <o:_AdHocReviewCycleID dt:dt="float">643113319</o:_AdHocReviewCycleID>
  <o:_EmailSubject dt:dt="string">2nd mail out material</o:_EmailSubject>
  <o:_AuthorEmail dt:dt="string">PLH@CDRH.FDA.GOV</o:_AuthorEmail>
  <o:_AuthorEmailDisplayName dt:dt="string">Hudson, Peter</o:_AuthorEmailDisplayName>
 </o:CustomDocumentProperties>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
 /* Page Definitions */
@page
	{mso-endnote-numbering-style:arabic;}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;
	mso-header-margin:1.0in;
	mso-footer-margin:1.0in;
	mso-even-footer:url("./3975b1-06-preclinical-2_files/header.htm") ef1;
	mso-footer:url("./3975b1-06-preclinical-2_files/header.htm") f1;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
@list l0
	{mso-list-id:63837260;
	mso-list-type:hybrid;
	mso-list-template-ids:-1647805360 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l1
	{mso-list-id:67969683;
	mso-list-type:hybrid;
	mso-list-template-ids:1373505704 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l2
	{mso-list-id:118686080;
	mso-list-type:hybrid;
	mso-list-template-ids:1610019748 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l3
	{mso-list-id:121385520;
	mso-list-type:hybrid;
	mso-list-template-ids:1080730610 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l3:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l4
	{mso-list-id:141894241;
	mso-list-type:hybrid;
	mso-list-template-ids:1501096212 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:39.0pt;
	mso-level-number-position:left;
	margin-left:39.0pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l5
	{mso-list-id:158355418;
	mso-list-type:hybrid;
	mso-list-template-ids:1093204488 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l5:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l6
	{mso-list-id:201216400;
	mso-list-type:hybrid;
	mso-list-template-ids:-1844527498 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l7
	{mso-list-id:353266715;
	mso-list-type:hybrid;
	mso-list-template-ids:1294486632 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l7:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l8
	{mso-list-id:368148210;
	mso-list-type:hybrid;
	mso-list-template-ids:917676842 -1701690240 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l8:level1
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.25in;}
@list l9
	{mso-list-id:629046834;
	mso-list-type:hybrid;
	mso-list-template-ids:2142157386 -1636534864 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l9:level1
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.25in;}
@list l10
	{mso-list-id:785856849;
	mso-list-type:hybrid;
	mso-list-template-ids:1228813332 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l10:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	margin-left:1.0in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l11
	{mso-list-id:1582906309;
	mso-list-type:hybrid;
	mso-list-template-ids:-1364715910 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l11:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l12
	{mso-list-id:1756439313;
	mso-list-type:hybrid;
	mso-list-template-ids:-590998176 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l12:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l13
	{mso-list-id:1869951810;
	mso-list-type:hybrid;
	mso-list-template-ids:1073781432 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l13:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l14
	{mso-list-id:1970746358;
	mso-list-type:hybrid;
	mso-list-template-ids:1654264904 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l14:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
</head>

<body lang=EN-US style='tab-interval:.5in'>

<div class=Section1>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;mso-pagination:none;
tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>Preclinical Review/additional information<o:p></o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center;mso-pagination:none;
tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;mso-bidi-font-weight:bold'>P</span><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>030004<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>DATE:</span></b><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span
style='mso-tab-count:2'>                        </span>7/25/03<span
style='mso-tab-count:4'>                                                </span><b
style='mso-bidi-font-weight:normal'> <o:p></o:p></b></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'>Review</span></b><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Additional information
regarding DMSO/coil compatibility, the effect of radiation on the polymer,
endotoxin quantities of the catheter and syringe, the amount of silicone oil placed
into the syringe and polymer solidification time was requested.<span
style="mso-spacerun: yes">  </span>As mentioned in the first mail-out, the
repeat injection issue related to DMSO potential toxicity is discussed.<span
style="mso-spacerun: yes">  </span>Finally, additional review information is
provided in this email as excerpted from the manufacturing reviewer/chemist’s
and preclinical reviewer’s review of the chemistry and toxicology of the
device.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><u><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>1. DMSO/coil compatibility<o:p></o:p></span></u></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>In the experiment the
sponsor used HPLC to detect any leachable chemical entities from platinum, GDC
or Cook fiber coils due to contact with DMSO.<span style="mso-spacerun: yes"> 
</span>The concomitant use of coils and the polymeric embolization agent is
likely to occur in the presurgical embolization of AVMs.<span
style="mso-spacerun: yes">  </span>A minor peak had been identified that was
different from control in 6 of 12 coils evaluated.<span style="mso-spacerun:
yes">  </span>I reviewed the control and suspect chromatograms.<span
style="mso-spacerun: yes">  </span>The control chromatogram shows a broad peak
in the area where the additional peak appears in 6 of 12 samples.<span
style="mso-spacerun: yes">  </span>In those 6 samples the peak appears to have
been split into two.<span style="mso-spacerun: yes">  </span>FDA agrees with
the sponsor’s chemist that the peak identifies a minor chemical entity and that
the splitting of the broad peak identified in the control into 2 minor peaks is
of minor importance, chemically, and does not necessarily indicate a new
degradation by-product or leached chemical.<span style="mso-spacerun: yes"> 
</span>The sponsor has adequately addressed the deficiency.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><u><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>2. Effect of radiation on
polymer<o:p></o:p></span></u></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>The sponsor had conducted
evaluations to determine if radiation could cause degradation of the polymer in
vivo.<span style="mso-spacerun: yes">  </span>Although the device is intended
for use as a presurgical embolication agent, in some cases a patient’s AVM may
not be resected due to various reasons.<span style="mso-spacerun: yes"> 
</span>In those situations, an alternative means for “resecting” the AVM is to
irradiate it.<span style="mso-spacerun: yes">  </span>Radiation causes the
tissue to undergo fibrosis and thereby, stabilization.<span
style="mso-spacerun: yes">  </span>The sponsor had not included the IR spectra
or GPC chromatograms to support their contention that the material had not
degraded after having been irradiated.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>The IR spectra provided of
material (n = 2) irradiated with 30 Gy were identical, or nearly
identical.<span style="mso-spacerun: yes">  </span>The control and irradiated
material spectra are qualitatively the same.<span style="mso-spacerun: yes"> 
</span>The GPC chromatograms (n = 2) of irradiated material and control EVOH
were nearly superimposable.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>In addition, the sponsor has
provided information that adequately addresses the concerns raised regarding
the endotoxin amounts, the silicone oil used in the syringe and the polymer
solidification time.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><u><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>3. Repeat injection issue<o:p></o:p></span></u></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>In the first mail-out FDA
provided the following draft preclinical question for consideration:<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt'>Preclinical
animal evaluations have shown that the rate and amount of DMSO can cause
vasospasm and vascular wall damage.<span style="mso-spacerun: yes"> 
</span>Patients undergoing staged embolization procedures for Cerebral
Arteriovenous Malformations will be exposed repeatedly to the potential for
DMSO-mediated vessel damage.<span style="mso-spacerun: yes">  </span>Do you
believe additional animal evaluation should be conducted to more completely
assess for repeat-DMSO vessel wall exposure and potential adverse effects? <span
style='color:red'><span style="mso-spacerun: yes"> </span></span>Do you have
any recommendations regarding the amount of DMSO a patient should be exposed to
over a 24 hour period or the length of time between embolization procedures?</span></i><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt'><o:p></o:p></span></i></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>FDA indicated that this
issue would be discussed in more detail in the second mail-out.<span
style="mso-spacerun: yes">  </span>The following information is a summary of
relevant data that you may find helpful in determining how you think this issue
is best resolved.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Onyx requires a two-step
procedure employing anhydrous DMSO.<span style="mso-spacerun: yes">  </span>MTI
data shows that the initial catheter-priming step used 0.2 – 0.26 mL DMSO
injected intra-arterially at &#8804; 0.4 mL/min.<span style="mso-spacerun:
yes">  </span>The second step involves slow injection (mean rates = 0.115
mL/min) of a mixture of EVOH polymer and tantalum powder dissolved in pure
DMSO.<span style="mso-spacerun: yes">  </span>Animal studies have shown that if
concentrated DMSO is given too quickly, severe vasospasm and angiotoxicity will
occur.<span style="mso-spacerun: yes">  </span>In early evaluations of the
embolic agent, Chaloupka et al studied the device in the swine rete
mirabile.<span style="mso-spacerun: yes">  </span>The investigators encountered
visualization, catheter-compatibility and vascular toxicity complications.<span
style="mso-spacerun: yes">  </span>The DMSO infusion caused moderate to severe
vasospasm immediately; subarachnoid hemorrhage or stroke occurred
frequently.<span style="mso-spacerun: yes">  </span>Histopathology showed
variable endothelial denuding, thrombosis, and internal elastic lamina
disruption acutely; an intense mixed inflammatory response with organized
thrombus formation and transmural necrosis with extravasation was noted in
subacute and chronic specimens.<span style="mso-spacerun: yes">  </span>The
investigators concluded that undiluted DMSO was angiotoxic.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Additional studies have
shown that if a low dose of DMSO is administered using a very slow injection
rate, vasospasm and angiotoxicity is not observed.<span style="mso-spacerun:
yes">  </span>Murayama et al., evaluated the embolic agent for acute and
chronic effects after intra-arterial delivery.<span style="mso-spacerun: yes"> 
</span>The study looked at the importance of slow infusion in reducing arterial
damage caused by concentrated DMSO.<span style="mso-spacerun: yes"> 
</span>Injections of 0.5 mL DMSO were given over 5, 15, 30, 60, and 120
seconds; the EVOH mixture used a priming dose of 0.3 mL DMSO administered over
40 seconds followed by 0.3-0.5 mL of the EVOH/DMSO mixture given over 20-40
seconds.<span style="mso-spacerun: yes">  </span>Special attention was directed
to findings of focal or diffuse angionecrosis, arterial revascularization, and
perivascular inflammation.<span style="mso-spacerun: yes">  </span>When 0.5 mL
DMSO alone was given over 5-15 seconds, vasospasm and endothelial necrosis developed.<span
style="mso-spacerun: yes">  </span>The same dose infused over 15 seconds
yielded focal vasospasm, but no laminal disruption or angionecrosis.<span
style="mso-spacerun: yes">  </span>No toxicity of any kind was noted if 0.5 mL
anhydrous DMSO was given slowly over 30, 60 or 120 seconds.<span
style="mso-spacerun: yes">  </span>The authors concluded that the two most
important elements in controlling vascular toxicity precipitated by intravenous
injection of concentrated DMSO were:<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-pagination:
none;mso-list:l3 level1 lfo13;tab-stops:-1.0in -.5in 0in list .5in left 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Contact
time with the arterial wall<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-pagination:
none;mso-list:l3 level1 lfo13;tab-stops:-1.0in -.5in 0in list .5in left 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>DMSO
volume<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Murayama et al. concluded
that “slow, controlled intra-arterial delivery of DMSO shows minimal
endothelial inflammatory response and no histological evidence of necrotizing
arteritis”.<span style="mso-spacerun: yes">  </span>The preclinical information
provided in the PMA and found in the scientific research literature clearly
indicates that DMSO can cause vascular toxicities if the rate of its infusion
is not carefully controlled.<span style="mso-spacerun: yes">  </span>In
addition, the preclinical information in the PMA also shows that if the rate of
injection is controlled, vasospasm and vascular toxicities are avoided in
single infusion experience.<span style="mso-spacerun: yes">  </span>Training physicians
with regard to the use of the product and how to avoid causing DMSO-mediated
vascular toxicity is important to the safe use of the product.<span
style="mso-spacerun: yes">  </span>The sponsor has an established training
program for physicians learning how to use the product that includes the
following elements:<br style='mso-special-character:line-break'>
<![if !supportLineBreakNewLine]><br style='mso-special-character:line-break'>
<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-pagination:
none;mso-list:l2 level1 lfo14;tab-stops:-1.0in -.5in 0in list .5in left 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Theoretical
presentation: includes discussion of Onyx formulations (Onyx 18 (6%) and Onyx
34 (8%) and rationale of when to use each formulation; overview of preclinical
testing; use of DMSO (research papers, animal studies, clinical experience to
date), and complete review of Onyx LES (liquid embolic system) tips and
techniques, i.e., material preparation, rate of injection of DMSO, compatible
micro-catheters, injection technique.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-pagination:
none;mso-list:l2 level1 lfo14;tab-stops:-1.0in -.5in 0in list .5in left 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>In
vitro bench workshop: bench model that replicates AVM flow characteristics used
to provided physicians experience with injecting Onyx 18 and Onyx 34 at various
flow rates<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-pagination:
none;mso-list:l2 level1 lfo14;tab-stops:-1.0in -.5in 0in list .5in left 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>In
vivo animal injections or clinical observation: physician is offered
opportunity to perform embolizations in the swine rete mirabile, renal arteries
or external carotid arteries, or to observe a clinical case performed by the
Onyx proctor.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-pagination:
none;mso-list:l2 level1 lfo14;tab-stops:-1.0in -.5in 0in list .5in left 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Case
review: training physician shares case films to provided reference regarding
clinical use of Onyx – overall clinical experience from Europe, selected case
videos, and films are reviewed<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-pagination:
none;mso-list:l2 level1 lfo14;tab-stops:-1.0in -.5in 0in list .5in left 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Clinical
representative attends the physician’s first case<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>And the product label
contains the following information regarding the use of DMSO:<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-pagination:
none;mso-list:l14 level1 lfo15;tab-stops:-1.0in -.5in 0in list .5in left 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>A
DMSO compatible delivery micro catheter that is indicated for use in the neuro
vasculature (e.g. Rebar™ or UltraFlow™ HPC catheters) is used to access the
embolization site.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-pagination:
none;mso-list:l14 level1 lfo15;tab-stops:-1.0in -.5in 0in list .5in left 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Direction
and Warning: Based on clinical practice, it is recommended that Onyx be
injected at a slow, steady rate of 0.16 mL/min (0.25 mL/90 sec).<span
style="mso-spacerun: yes">  </span>Do not exceed 0.3 mL/min.<span
style="mso-spacerun: yes">  </span>Do not exceed 0.3 mL/min injection
rate.<span style="mso-spacerun: yes">  </span>Animal studies have shown that
rapid injection of DMSO into the vasculature may lead to vasospasm and /or
angionecrosis.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>The training program and the
label instructions/warnings appear to adequately inform the user about the
dangers of rapid DMSO vascular infusion.<span style="mso-spacerun: yes"> 
</span>However, little research information or clinically meaningful
information is available regarding the safety of repeat infusions of DMSO as
might occur during staged embolizations of the product.<span
style="mso-spacerun: yes">  </span>In an Onyx-unrelated animal assessment of
the repeat intravenous administration of DMSO, Willson et al found that
undiluted DMSO given to dogs at 0.3, 0.6, 1.2 and 2.4 g/kg/day six times per
week for 4 weeks caused injection-site vein occlusion.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Limited information to
address repeat DMSO injection as related to the Onyx device and its potential
resultant toxicity was provided by the sponsor.<span style="mso-spacerun:
yes">  </span>In tissue surgically excised from 7 patients of the Mexico City Embolyx
Pilot Study and the International Brain Arteriovenous Malformation Clinical
study the investigators assessed Onyx for its potential chronic, histotoxic
effects.<span style="mso-spacerun: yes">  </span>Seven BAVMs embolized with
Onyx were surgically excised and submitted for evaluation to a board certified
histopathologist.<span style="mso-spacerun: yes">  </span>Prior to surgery, 1
of 7 patients received a single embolization treatment, 2 of 7 received 2
treatments, 1 of 7 received 3 treatments and 3 of 7 received 4 treatments.<span
style="mso-spacerun: yes">  </span>The timing between embolization and surgery
ranged from 1 week to 19 months while all patients had pre-surgical
embolization periods of at least 3 months, i.e., no one had one embolization
procedure and then within 1 week went to surgery whereas some patients may have
had multiple embolization procedures with the last one being 1 week prior to
surgery.<span style="mso-spacerun: yes">  </span>There were no indications of
vascular necrosis, rupture or extravasation of the Onyx material.<span
style="mso-spacerun: yes">  </span>Numerous vessels were observed with
disruption of the internal elastic lamina, but there did not appear to be any
serious adverse effect on the vessel wall.<span style="mso-spacerun: yes"> 
</span>The information is obviously very limited.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-hyphenate:none;tab-stops:-.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>A review of CT, MRI and flat
film skull x-rays obtained from patients whose BAVMs were treated with Onyx or
n-BCA was performed for MTI by a central reader to determine if any direct neurotoxicity
due to Onyx can be detected in the brain post-embolization.<span
style="mso-spacerun: yes">  </span>A total of 54 patients were studied in the
Onyx group and 19 in the n-BCA group (total = 73).<span style="mso-spacerun:
yes">  </span>The central reader was blinded as to treatment.<span
style="mso-spacerun: yes">  </span>All MRI and CT studies were evaluated for
the presence or absence of gliosis, encephalomalacia, edema, leptomeningeal or
parenchymal enhancement and hemorrhage. These parameters were pre-defined based
on specific imaging characteristics.<span style="mso-spacerun: yes"> 
</span>The average time post-embolization for all imaging studies was 23
months, with a range of 9 to 50 months.<span style="mso-spacerun: yes"> 
</span>Forty-one patients of the 73 had imaging findings that required an
assessment as to whether the finding was due to the device.<span
style="mso-spacerun: yes">  </span>Twelve of the 19 n-BCA patients had imaging
changes that were due to: concurrent neurosurgical resection of the AVM,
changes in the brain related to neurosurgery, or due to the natural history of
the AVM.<span style="mso-spacerun: yes">  </span>Twenty-nine of 54 patients in
the Onyx groups demonstrated imaging findings post-embolization that were not
present pre-embolization.<span style="mso-spacerun: yes">  </span>The reader
(Director, Clinical Image Processing Service for UCLA Department of
Radiological Sciences) asserts that “in all cases the etiology of the
post-embolization findings was found to be due to events unrelated to the
presence of Onyx.”<span style="mso-spacerun: yes">  </span>The findings were
believed to be due to radiosurgery, surgical resection of the AVM and the
natural history of the AVM.<span style="mso-spacerun: yes">  </span>An FDA
radiologist reviewed the images and found no reasons to disagree with the
central reader’s interpretation that the image post-embolization observations
were due to events unrelated to the presence of Onyx.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>The following parameters of
the investigational study should be taken into account:<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Number of <span
style='mso-tab-count:3'>                               </span>n-BCA<span
style='mso-tab-count:1'> </span>(n = 54)<span style='mso-tab-count:2'>                        </span>Onyx
(n = 46)<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><u><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>embolization procedures<span
style='mso-tab-count:1'>           </span>#<span style='mso-tab-count:1'>          </span>%<span
style='mso-tab-count:3'>                                 </span>#<span
style='mso-tab-count:1'>          </span>%<o:p></o:p></span></u></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span>1<span style='mso-tab-count:3'>                                  </span>34<span
style='mso-tab-count:1'>        </span>63<span style='mso-tab-count:3'>                                </span>26<span
style='mso-tab-count:1'>        </span>56.5<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span>2<span style='mso-tab-count:3'>                                  </span>9<span
style='mso-tab-count:1'>          </span>16.7<span style='mso-tab-count:3'>                             </span>11<span
style='mso-tab-count:1'>        </span>23.9<span style='mso-tab-count:2'>                 </span><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span>3<span style='mso-tab-count:3'>                                  </span>7<span
style='mso-tab-count:1'>          </span>13<span style='mso-tab-count:3'>                                </span>6<span
style='mso-tab-count:1'>          </span>13<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span>4<span style='mso-tab-count:3'>                                  </span>2<span
style='mso-tab-count:1'>          </span>3.7<span style='mso-tab-count:3'>                               </span>1<span
style='mso-tab-count:1'>          </span>2.2<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span>5<span style='mso-tab-count:3'>                                  </span>2<span
style='mso-tab-count:1'>          </span>3.7<span style='mso-tab-count:3'>                               </span>1<span
style='mso-tab-count:1'>          </span>2.2<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span>6<span style='mso-tab-count:3'>                                  </span>0<span
style='mso-tab-count:1'>          </span>0<span style='mso-tab-count:3'>                                  </span>0<span
style='mso-tab-count:1'>          </span>0<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span>7<span style='mso-tab-count:3'>                                  </span>0<span
style='mso-tab-count:1'>          </span>0<span style='mso-tab-count:3'>                                  </span>1<span
style='mso-tab-count:1'>          </span>2.2<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>From the sponsor’s clinical
experience outside of the United States:<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Number of <span
style='mso-tab-count:5'>                                                       </span>Onyx
(n = 161)<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><u><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>embolization procedures<span
style='mso-tab-count:3'>                                   </span>#<span
style='mso-tab-count:2'>                      </span>%<span style='mso-tab-count:
1'>         </span><o:p></o:p></span></u></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span>1<span style='mso-tab-count:5'>                                                          </span>113<span
style='mso-tab-count:2'>                  </span>70.2<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span>2<span style='mso-tab-count:5'>                                                          </span>32<span
style='mso-tab-count:2'>                    </span>19.9<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span>3<span style='mso-tab-count:5'>                                                          </span>12<span
style='mso-tab-count:2'>                    </span>7.4<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
1'>            </span>&gt;3<span style='mso-tab-count:5'>                                                        </span>4<span
style='mso-tab-count:2'>                      </span>2.5<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>So, the information gathered
in the sponsor’s U.S. clinical study and their experience outside the U.S.
clearly indicates that although the majority of AVM patients will undergo one
embolization procedure, there is a subpopulation of individuals that will
undergo two or more infusions of the embolic agent.<span style="mso-spacerun:
yes">  </span>The mean volume of Onyx injected in this [U.S.] investigational
study was 0.5 mL and the mean volume of DMSO injected was 0.27 mL, whereas
clinical experience outside the U.S. found that the mean volume of DMSO per
treatment was 1.57 mL and the maximum dose of DMSO ever delivered was 8.36 mL.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>It could be argued that
since the embolic agent is targeted to a vascular abnormality that the
physician intends to remove from the patient, long term evaluation regarding
repeat DMSO injections is of little interest.<span style="mso-spacerun: yes"> 
</span>However, not all patients in the study went on to have their AVM
surgically excised.<span style="mso-spacerun: yes">  </span>Of the 100 patients
in the ITT population, 86 had total resection and 89 had total or partial
resection.<span style="mso-spacerun: yes">  </span>The patients enrolled in the
study were identified as surgical candidates but because surgical resection was
not in the patients’ best interest, surgical resolution did not occur in every
case.<span style="mso-spacerun: yes">  </span>With respect to vasculature that
has been embolized with DMSO more than once we have very limited information in
terms of numbers of patients and in length of time of follow-up.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Please consider this
information in preparation for discussion of the repeat-injection DMSO toxicity
panel question.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><u><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>4. Chemistry of Device <o:p></o:p></span></u></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Ethylene vinyl alcohol
copolymer (EVOH) is synthesized by polymerizing a mixture of ethylene gas and
vinyl acetate.<span style="mso-spacerun: yes">  </span>The resulting ethyl
vinyl acetate is treated in a basic pH environment with sodium hydroxide and
methanol to hydrolyze the acetate from the polymeric chain resulting in ethyl
vinyl alcohol.<span style="mso-spacerun: yes">  </span>The EVOH polymer is
washed with methanol to remove the acetate and other low molecular weight
oligomers.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>The EVOH co-polymer requires
the use of anhydrous DMSO (Onyx = EVOH in DMSO plus tantalum for
radiopacification) as a solvent for delivery through the micro-catheter to the
AVM site.<span style="mso-spacerun: yes">  </span>If Onyx comes into contact
with saline, it will immediately precipitate and block the catheter.<span
style="mso-spacerun: yes">  </span>A small amount of anhydrous DMSO (0.2-0.26
mL) is used to prime the micro-catheter.<span style="mso-spacerun: yes"> 
</span>After Onyx reaches the aqueous environment of the embolization site,
DMSO from the EVOH/DMSO mixture will be diluted by water in the blood and
surrounding tissues.<span style="mso-spacerun: yes">  </span>Water contact will
cause the EVOH polymer to precipitate and produce an embolus that will conform
to the tissues of the embolization site.<span style="mso-spacerun: yes"> 
</span>Formation of the embolic plug begins at its outer surfaces and proceeds
inward.<span style="mso-spacerun: yes">  </span>Complete embolus formation
requires a prolonged period of time, from 3-20 minutes, depending on blood flow
and the amount of material injected.<span style="mso-spacerun: yes"> 
</span>Micronized tantalum is added to the EVOH/DMSO solution to provide for
fluoroscopic visualization.<span style="mso-spacerun: yes">  </span>It is
important to note that the catheter priming amount of DMSO represents the free,
non-solvent DMSO device component in that it is used simply to prime the
catheter.<span style="mso-spacerun: yes">  </span>The priming volume of DMSO
will be readily transported from the embolization site intravascularly and/or
into the interstitial space of the site.<span style="mso-spacerun: yes"> 
</span>DMSO solvating the EVOH will diffuse more slowly from the site, than the
free DMSO priming amount, as it is gradually released from the precipitating
embolus.<span style="mso-spacerun: yes">  </span><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Master file and release
specifications for each device component have been reviewed.<span
style="mso-spacerun: yes">  </span>From the manufacturing/polymer chemist’s
perspective, the “three major components of the subject device, Ethylene Vinyl
Alcohol Copolymer (EVOH), Dimethyl Sulfoxide (DMSO) and Tantalum do not contain
significant amounts of impurities and are spectrascopically pure materials.”<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>There are 2 formulations
used in the Onyx LES for AVM treatment: Onyx 18 and Onyx 34.<span
style="mso-spacerun: yes">  </span>The maximum concentration of DMSO is
approximately 90% by volume.<span style="mso-spacerun: yes">  </span>In MTI’s
studies to date the average amount of DMSO used per treatment was 1.57 mL and
the maximum volume of DMSO used in any one treatment was 8.36 mL (data
collected from 222 procedures).<span style="mso-spacerun: yes">  </span>For the
calculation of the potential maximum DMSO dose observed in AVM treatments, 8.36
mL x 1.10 (specific gravity of DMSO) equals 9.2 g DMSO, thus yielding (9.2 g/70
kg) a maximal DMSO dose of <b style='mso-bidi-font-weight:normal'><u>131 mg/kg</u></b>.<span
style="mso-spacerun: yes">  </span>If this maximum dose is calculated to be
used as the first of a series of staged embolizations, it is reasonable to
assume that subsequent embolization treatments would require smaller, more
average, quantities of Onyx.<span style="mso-spacerun: yes">  </span>Using the
average amount of DMSO (1.57 mL) used for 3 additional treatments (1.57 mL x 3
treatments x 1.10 [spec. gravity of DMSO]), plus 9.2 g DMSO per the first
treatment, the total maximal dose of DMSO a patient would be likely to be
exposed to is 14.37 g DMSO/70 kg, or <b style='mso-bidi-font-weight:normal'><u>205
mg/kg</u></b>.<span style="mso-spacerun: yes">  </span>[Please note that these
values are numerically larger than what was used in the U.S. clinical study,
i.e., 0.27 mL free DMSO plus 0.5 mL Onyx.]<span style="mso-spacerun: yes"> 
</span>To calculate a lower range value, using the mean, average dose for the
first treatment instead of the maximal dose ever observed, the lower potential
DMSO exposure would be, 1.57 mL x 1.10 = 1.73/70 kg = 0.025 g/kg x 4 treatments
= <b style='mso-bidi-font-weight:normal'><u>100 mg/kg</u></b>.<span
style="mso-spacerun: yes">  </span>Therefore the range of DMSO concentration
that a patient could be exposed to is <b style='mso-bidi-font-weight:normal'><u>100-205
mg/kg</u></b>.<span style="mso-spacerun: yes">  </span>It is important to note
that the embolization procedures would be done over a period of time and the
patient would not be exposed to the 100-205 mg/kg total all at once.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Metabolic studies in man and
lower animals indicate that the primary metabolites of DMSO are dimethyl
sulfone (DMSO</span><sub><span style='font-size:12.0pt'>2</span></sub><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>) and dimethyl sulfide
(DMS).<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><u><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>5. DMSO Biocompatibility:
Toxicities of DMSO and DMSO metabolites<o:p></o:p></span></u></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>MTI provided a white paper
on DMSO toxicity which identified research information regarding the
absorption, distribution, metabolism, and excretion of DMSO.<span
style="mso-spacerun: yes">  </span>The following information is a very brief
summary of the most pertinent information of that white paper.<span
style="mso-spacerun: yes">  </span>DMSO, when used in the treatment of
interstitial cystitis in humans is considered a drug.<span style="mso-spacerun:
yes">  </span>For a point of comparison, Rimso-50</span><sup><span
style='font-size:12.0pt'>®</span></sup><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'> consists of a 50% solution of DMSO, and as
instilled in the bladder as a 50 mL dose, equals a 393 mg/kg dose for a 70 kg
person.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>DMSO has chemical properties
which facilitate its absorption into and distribution throughout biological
systems by all routes of administration.<span style="mso-spacerun: yes"> 
</span>DMSO can also carry other substances along with it due to its solvating
power.<span style="mso-spacerun: yes">  </span>DMSO is a polar nucleophile
which has free electron pairs at its sulfur and oxygen terminals.<span
style="mso-spacerun: yes">  </span>It is considered an aprotic solvent since it
does not normally donate hydrogen atoms in chemical reactions.<span
style="mso-spacerun: yes">  </span>Hydrogen bonding of DMSO with water is 1&#8531;
times stronger than the hydrogen boding between water molecules themselves,
thus yielding DMSO’s hygroscopic character.<span style="mso-spacerun: yes"> 
</span>Intravenous administration of DMSO appears to be well-tolerated at
concentrations lower than 50%.<span style="mso-spacerun: yes">  </span>Higher
concentrations, given repeatedly, injure the injected vessels causing fibrosis
proportional to the concentration and number of injections.<span
style="mso-spacerun: yes">  </span>Persistent damage to the blood vessel causes
a narrowing of the lumen.<span style="mso-spacerun: yes">  </span>As noted
above, the Willson study observed injection site vein occlusion in dogs given
daily injections of DMSO for 4 weeks.<span style="mso-spacerun: yes"> 
</span>The injection rate of DMSO has been observed to determine toxicity.<span
style="mso-spacerun: yes">  </span>As noted in a 1971 text, <i
style='mso-bidi-font-style:normal'>Toxicology of DMSO in Animals</i> (Mason), a
5 mL rapid intravenous infusion of DMSO caused death in a dog whereas a dose of
100 mL infused over 4 hours did not cause death.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Distribution studies
regarding DMSO reveal that the molecule is rapidly distributed in a wide-spread
manner.<span style="mso-spacerun: yes">  </span>Denko et al. found that DMSO
accumulated more in soft tissues and it was found in tissues with low and high
lipid content.<span style="mso-spacerun: yes">  </span>Tissue vascularity or
permeability appeared to offer no preferred mode of action.<span
style="mso-spacerun: yes">  </span>In a study by Nishimura et al. looking
specifically at distribution of DMSO in brain and vascular tissue in the rat,
calculated tissue (muscle, liver and gray matter) to plasma ratios were
observed to be 1:1 two hours after infusion (of a 1g/kg/hour) was
initiated.<span style="mso-spacerun: yes">  </span>White matter approached this
ratio after one hour and had declined some by 2 hours.<span
style="mso-spacerun: yes">  </span>In the mouse, peak plasma concentration was
reached one minute after a bolus injection into the tail vein and it diminished
in a biexponential fashion; its rapid distributive phase showed a t½ of 1.5
minutes, while the longer terminal half-life was 90 minutes.<span
style="mso-spacerun: yes">  </span>In summary, MTI believes that the DMSO in
the Onyx solution will be distributed rapidly by the vascular system, a portion
likely bound to serum or plasma proteins, or dispersed into interstitial spaces
of surrounding tissues.<span style="mso-spacerun: yes">  </span>The priming
dose (of the catheter) will likely be distributed via the vascular system very
quickly whereas the DMSO that slowly elutes from the embolus will likely gain
entrance to the endothelial lining cells of the blood vessel and to the
interstitial space.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>Many metabolic studies in
man and animals show that the primary metabolites of DMSO are dimethyl sulfone
and dimethyl sulfide.<span style="mso-spacerun: yes">  </span>The extent to
which DMSO is converted to dimethyl sulfone by non-primates seems to vary
somewhat by route and species.<span style="mso-spacerun: yes">  </span>All
studies reviewed in the white paper indicated that DMSO is not excreted
unchanged to some extent, most of it will be either oxidized to dimethyl
sulfone and excreted in the urine or reduced to dimethyl sulfide and
exhaled.<span style="mso-spacerun: yes">  </span>The garlic-breath of
individuals treated with DMSO is thought to result from the conversion to
dimethyl sulfide.<span style="mso-spacerun: yes">  </span>Although unsupported
by data, MTI believes, based on animal studies including human and non-human
primates, that approximately half of the DMSO in Onyx will not be metabolized
with 20-25% being converted to dimethyl sulfone and a small fraction being
converted to dimethyl sulfide.<span style="mso-spacerun: yes">  </span>Dimethyl
sulfoxide is a constituent of plant materials.<span style="mso-spacerun: yes"> 
</span>Dimethyl sulfone is found in milk and dimethyl sulfide has been found in
prepared foods.<span style="mso-spacerun: yes">  </span>The manufacturer of the
DMSO provided limited LD</span><sub><span style='font-size:12.0pt'>50</span></sub><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'> information regarding the
acute toxicity of dimethyl sulfide in the rat.<span style="mso-spacerun: yes"> 
</span>The oral, inhalation and dermal values were 3.7 g/kg, 40,250 ppm, and
10.2 g/kg, respectively.<span style="mso-spacerun: yes">  </span>The small amounts
of dimethyl sulfone and dimethyl sulfide should not, based on available toxicology
information, cause risk to the patient.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>LD</span><sub><span
style='font-size:12.0pt'>50</span></sub><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'>s after intravenous dosing reveals that anhydrous
DMSO caused acute toxicity in cats, dogs, monkeys, rabbits and rats in the
range of <b style='mso-bidi-font-weight:normal'><u>2.5 g/kg-11g/kg</u></b>.<span
style="mso-spacerun: yes">  </span>Some investigators found that repeated
intravenous injections of undiluted DMSO were damaging to the veins of dogs and
rats. However other investigators found no negative effects of injecting 40%
DMSO into dogs for 33 days.<span style="mso-spacerun: yes">  </span>The sponsor
cites a 1963 reference that determined the LD</span><sub><span
style='font-size:12.0pt'>0.1</span></sub><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt'>, or that dose likely to kill 1/1000 animals dosed,
for anhydrous DMSO after intravenous administration to be 400 mg/kg in the
mouse.<span style="mso-spacerun: yes">  </span>As the sponsor notes, this dose
is approximately 3 times that of the largest single DMSO dosage used in Onyx
clinical experience to date (i.e., 131 mg/kg) and 14-16 times the average
dosages for Onyx clinical treatments.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>There is sufficient evidence
provided in the research literature that demonstrates DMSO to be
hemolytic.<span style="mso-spacerun: yes">  </span>A number of animal studies
noted hematuria and hemoglobinuria – specifically after intravenous
administration.<span style="mso-spacerun: yes">  </span>Emmerling et al in a
1991 study report to NCI found that male rats given 70% DMSO via a rate of 2
mL/kg/hr/120 hrs showed marked decreases in hematocrit and hemoglobin by the
second day.<span style="mso-spacerun: yes">  </span>In a study by Bennet et al
concentrations of DMSO of 10, 20 and 40% infused at 1g/kg caused decreases in
hematocrit of 1.5, 4.9 and 5% in humans.<span style="mso-spacerun: yes"> 
</span>In the study by Willson, anemia, hemoglobinuria, bilirubinuria,
increased SGOT levels and slight liver pathology was observed at a dose of 0.3
g/kg/day/6 days/week/4 weeks.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>In conclusion, Onyx
administration is likely to produce some hemolysis, primarily after the priming
dose is given.<span style="mso-spacerun: yes">  </span>In addition, endothelial
cell damage is possible but should be minimized by adherence to the slow rate
of administration determined in the sponsor’s animal model investigations
evaluating for angiotoxicity.<span style="mso-spacerun: yes">  </span>The
severity of vasospasm and the occurrence of angionecrosis in swine were reduced
when the volume of DMSO was reduced from 0.8 to 0.5 mL.<span
style="mso-spacerun: yes">  </span>As a result of the recommendation by
Murayama et al, that 0.3 mL delivered over 40 seconds was a safe dose, the
recommended priming doses now used for Onyx is 0.26 over 40 seconds.<span
style="mso-spacerun: yes">  </span>The amount of DMSO a patient has been maximally
exposed to falls 3-4 times below levels noted in animal toxicology studies to
cause adverse effects.<span style="mso-spacerun: yes">  </span>As evidenced by
the sponsor’s U.S. clinical study, the amounts of DMSO most commonly used in
the presurgical embolization of AVMs is much lower than the maximal amount
reported.<span style="mso-spacerun: yes">  </span>The extensive
biocompatibility assessments and animal performance evaluations indicate that
the product was biocompatible and did not cause adverse tissue responses
different than, or greater than what is seen with approved embolic agents.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;tab-stops:-1.0in -.5in 0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.0in 6.5in'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

</div>

</body>

</html>
